| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.50 | 72.4% |
| Total Income | 0.50 | 72.4% |
| Expenditure | 4.10 | 0.5% |
| PBT | -3.52 | 6.6% |
| Net Profit | -3.52 | 6.6% |
| OPM | — | |
| NPM | — | |
| EPS | -0.90 | 104.5% |
SeaStar Medical Reports Q1 2026 Revenue Up 69% YoY
14 May 2026 · 14 May, 1:48 am
Summary
SeaStar Medical Holding Corporation reported financial results for the three months ended March 31, 2026. Net revenue for Q1 2026 was $0.5 million, a 69% increase compared to the same period in 2025. The company is advancing enrollment in the NEUTRALIZE-AKI pivotal trial and initiated efforts for a modular PMA submission. The net loss for the quarter was approximately $3.5 million, or $0.90 per share. Cash reserves stood at $9.3 million as of March 31, 2026.
Key Highlights
- 1
SeaStar Medical's QUELIMMUNE customer base expanded, adding 7 top-rated children’s hospitals in Q1 2026.
- 2
First quarter 2026 net revenue for QUELIMMUNE product sales reached $0.5 million, a 69% increase compared to Q1 2025.
- 3
Enrollment advanced in the NEUTRALIZE-AKI pivotal trial evaluating SCD therapy for adult patients with AKI.
- 4
Efforts were initiated for the submission of a modular post-marketing application (PMA).
- 5
The company reported cash of $9.3 million as of March 31, 2026.
- 6
Net loss for the three months ended March 31, 2026, was approximately $3.5 million, or $0.90 per share.
Management Comments
Eric Schlorff
“Our QUELIMMUNE customer base continues to grow with a groundswell of enthusiasm among key experts that is driving our penetration into new accounts,” said Eric Schlorff, CEO of SeaStar Medical. “We saw a significant jump in revenue of 69% this quarter versus the first quarter of last year. The trajectory is very encouraging as we consider the next opportunity in the adult market, which is approximately 50 times larger than the pediatric AKI market.” Mr. Schlorff continued, “We are working diligently to enroll adult patients with AKI in the NEUTRALIZE-AKI pivotal trial. We have activated multiple new clinical sites in the last six months and believe that a successful outcome of this trial would position us to file a PMA with the FDA for the adult AKI indication in 2027. Our success in building the QUELIMMUNE market now will provide critical support for this potential future opportunity.”
Informational and educational content only. Not investment advice.